Wechselwirkungen · Tesavel
Tesavel 25 mg film-coated tablets Tesavel 50 mg film-coated tablets Tesavel 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-119787 · Präparat HOS-095021
Ciclosporin: A study was conducted to assess the effect of ciclosporin, a potent inhibitor of p-glycoprotein, on the pharmacokinetics of sitagliptin. Co-administration of a single 100 mg oral dose of sitagliptin and a single 600 mg oral dose of ciclosporin increased the AUC and Cmax of sitagliptin by approximately 29 % and 68 %, respectively. These changes in sitagliptin pharmacokinetics were not considered to be clinically meaningful. The renal clearance of sitagliptin was not meaningfully altered. Therefore, meaningful interactions would not be expected with other p-glycoprotein inhibitors.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-01T12:05:00Z · SHA-256 8addcb407da8089454371dd22f7432a978ec735825167d238bfcd87dd57f7eb3 · Passage ea5930922accb6e665bd5dfce759b3989904fccb7dbe59f6a4314d214f67fef9 · Zeichen 1525–2124 im Abschnitt